A sensitive screening approach for lung cancer could markedly reduce the high mortality rate for this disease. Previous studies have shown that methylation of gene promoters is present in exfoliated cells within sputum prior to lung cancer diagnosis. The purpose of the current study is to conduct a nested case-control study of incident lung cancer cases from an extremely high-risk cohort for evaluating promoter methylation of 14 genes in sputum. Controls (n = 92) were cohort members matched to cases (n = 98) by gender, age, and month of enrollment. The comparison of proximal sputum collected within 18 months to >18 months prior to diagnosis showed that the prevalence for methylation of gene promoters increased as the time to lung cancer diagnosis decreased. Six of 14 genes were associated with a >50% increased lung cancer risk. The concomitant methylation of three or more of these six genes was associated with a 6.5-fold increased risk and a sensitivity and specificity of 64%. This is the first study to prospectively examine a large panel of genes for their ability to predict lung cancer and shows the promise of gene promoter hypermethylation in sputum as a molecular marker for identifying people at high risk for cancer incidence. (Cancer Res 2006; 66(6): 3338-44) 
Introduction
Lung cancer is the leading cause of cancer mortality in the U.S. and 1.5 million deaths are projected worldwide from this disease by 2010 (1, 2) . The overall 5-year survival rate for lung cancer is <15%, due largely to the late stage at which most patients are diagnosed and the lack of effective treatments for this systemic disease. A validated screening approach for lung cancer could substantially reduce the high mortality rate from this disease. The benefit of early detection is seen in patients with stage I tumors (<3 cm) in which surgical resection is the treatment option of choice, and the rate of recurrence within 5 years is <50% (3) (4) (5) . With the adoption of adjuvant chemotherapy for these early stage lung cancer patients, the rate of recurrence should decline further (6) .
Cytologic and/or genetic biomarkers for lung cancer risk detected in sputum could complement radiological imaging and bronchoscopy for detecting early lung tumors (7) . Previous studies have shown that cytologic atypia present in epithelial cells exfoliated into sputum precedes lung cancer diagnosis (8) . Transcriptional silencing of genes by CpG island methylation is now recognized as a crucial component in lung cancer initiation and progression (9, 10) . The development of the methylation specific PCR (MSP) assay has allowed for the assay of methylation of specific genes in sputum where epithelial cells comprise only a fraction of the cellular content (11) . In a small proof-of-concept study, methylation of the CDKN2A (p16) or O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoters was detected in sputum up to 3 years prior to the diagnosis of squamous cell carcinoma (12) . The evaluation of cancer-free individuals who were at risk for lung cancer because of smoking and/or exposure to radon through uranium mining revealed methylation of the p16 and MGMT genes in 15% and 25% of sputum samples, respectively. The most striking difference seen between lung cancer cases and controls was the detection of both methylated genes in 48% of sputum samples from cases but in only 3% of controls. Follow-up revealed three lung cancers diagnosed in controls 1 to 3 years after sputum collection with the MGMT gene being methylated in two of these individuals.
Several subsequent small studies support the promise of genespecific methylation as a biomarker for predicting lung cancer (13) (14) (15) (16) . In those studies, methylation of p16 and other genes was assessed in sputum from people at high risk for lung cancer. Follow-up conducted in two of those studies revealed that of the eight people positive for methylation of p16 in their sputum, three developed lung cancer f1 year after sputum collection (13) . In addition, of the five people positive for methylation of the ras effector homologue 1 (RASSF1A) gene, three developed lung cancer 12 to 14 months after sputum collection (16) . Methylation also persists after smoking cessation based on similar prevalence in sputum from current versus former smokers (17) . Together, these studies indicate that the detection of gene promoter methylation in sputum could be a powerful approach to population-based screening for the early detection of lung cancer.
The well-documented field cancerization seen in lungs from smokers, stemming from the exposure of the entire respiratory tract to inhaled carcinogens within cigarette smoke, presents an obstacle to the early detection of lung cancer (18) . The generation of multiple, independently initiated sites throughout the lungs of people with a long history of smoking likely accounts for detecting methylation of genes such as p16 that is inactivated in the earliest stages of preinvasive disease (19) . The use of promoter methylation as a biomarker for early detection of lung cancer may therefore require a panel of genes whose presence in sputum confer a high enough sensitivity and specificity for distinguishing very advanced dysplasia or early lung cancer from the large ''at risk'' population (20) . A critical step in the development of a gene panel requires testing the biomarker in a prospective population-based study (21) . The University of Colorado Specialized Program of Research Excellence in Lung Cancer initiated a cohort study in 1993 to assess whether sputum cytology or other molecular markers could be used to predict early lung cancer (17) . The purpose of the current investigation was to conduct a nested, case-control study of incident lung cancer cases from this cohort to evaluate promoter methylation of 14 genes in sputum.
Materials and Methods
Study population. The University of Colorado Cancer Center Sputum Screening Cohort Study is an ongoing prospective study initiated in 1993 to determine whether biomarkers identified within sputum could predict future lung cancer development. The study methodology has been described previously (8) . Briefly, subjects were recruited from community and academic pulmonary clinics primarily in the Denver, CO metropolitan area. At enrollment, subjects were 25 years or older with a cigarette smoking history of z30 pack years, and with pulmonary air flow obstruction documented by a spirometry finding of forced expiratory volume in 1 second (FEV1) of 75% or lower than predicted for age, and an FEV1/FVC ratio of V0.75. Subjects who had a diagnosis of cancer within 5 years prior to the time of recruitment (excluding non-melanoma skin cancer), a current acute respiratory infection, or who were judged by their physician to have a life expectancy of <5 years were excluded from the study. Participants were provided with two containers filled with a fixative solution of 2% carbowax and 50% alcohol (Saccomanno's fixative) and were instructed to collect an early morning, spontaneous cough sputum specimen for 6 consecutive days (3 days' collection into the first container and 3 days' collection into the second container). Material from the second 3-day pooled sputum specimen was sampled for this study (22) .
Cohort members were contacted once a year to ask for their continued participation and to provide another sputum sample. Other cohort members were followed by active methods such as mail and by passive methods such as the matching to the Colorado Department of Public Health and Environment Vital Statistics records (through February 2005), the National Death Index (searched through December 2001), and the Colorado Central Cancer Registry (searched through December 2004). Among the 3,259 cohort members in this analysis, there were 1,353 documented deaths and 182 documented lung cancers. Cases in this analysis were those cohort members who contributed a sputum sample, who were not known or suspected to have a cancer at enrollment, and who were subsequently diagnosed with incident lung cancer after enrollment. Controls were cohort members matched to cases by gender, age, and month of enrollment. There were 121 cases and 120 matched controls selected for this study. Among those, DNA from 50 subjects was of insufficient quality to obtain results in the MSP assays. These subjects did not differ from the cases and controls that were evaluated for methylation with respect to demographics, clinical history, sputum cytology, or smoking history (P > 0.05). Two controls were found to be incident cases with ongoing follow-up during the course of the study. In addition, another case was determined to be a carcinoma in situ and was excluded. Therefore, the final analysis set included 98 cases and 92 controls. The Colorado MultiInstitutional and Lovelace Respiratory Research Institute (LRRI) Review Boards approved this study. Participants previously gave their consent for the use of sputum samples to investigate potential biomarkers in the University of Colorado Cancer Center Sputum Screening Cohort Study.
Sputum processing and MSP. Sputum samples were stored in Saccomanno's fixative. Four slides were prepared from sputum samples and stained using the Papanicolaou technique as described elsewhere (23) . Slides were independently screened by cytotechnologists as: not adequate for diagnosis, normal, squamous metaplasia, mild atypia, moderate atypia, severe atypia, or carcinoma (23, 24) . An aliquot from all sputum samples, irrespective of adequacy, for each study subject was taken, and DNA was isolated by protease digestion followed by phenol chloroform extraction and ethanol precipitation. DNA (6 Ag) was sent to investigators at the LRRI for methylation assays. Samples were labeled only with study-specific coded identifiers to blind the LRRI investigators from case or control status. Assays were done with both cases and controls included in each batch.
Fourteen genes were selected for evaluation based on their prevalence in lung tumors (z25%), diversity of function, and timing for inactivation during lung cancer development when known (19, (25) (26) (27) (28) (29) (30) (31) (32) (33) . The BETA3 and helix-loop-helix (HLHP) genes (34, 35) were identified through a genomewide screening approach for methylation; however, the prevalence for methylation of these genes in lung cancer has not been reported yet. 4 Nested MSP was used to detect methylated alleles in DNA recovered from the sputum samples. We used our nested MSP assay described previously (12, 17) because of its increased sensitivity for the detection of promoter hypermethylation in biological fluids. In order to conserve DNA and effort, stage 1 multiplex PCR reactions amplifying four genes at once were done. DNA (120-150 ng) was used for stage 1 PCR following modification with bisulfite. PCR primers for stage 1 and 2 amplification of the p16, MGMT, death associated protein kinase (DAPK), RASSF1A, PAX5 a, and PAX5 b genes have been described elsewhere (12, 17, 25) . PCR primers and conditions used for amplification of the GATA4, GATA5, secreted frizzle like protein 1 (SFRP1), laminin C2 (LAMC2), insulin-like growth factor receptor 3 (IGFBP3), H-cadherin, BETA 3, and HLHP genes are available from the corresponding author. Conditions for all stage 1 multiplexes were optimized through primer design and PCR conditions to achieve equal product intensity. These optimal conditions ensured a similar sensitivity for the detection of methylated alleles across genes in the stage 2 MSP assay. All stage 2 PCR reactions were conducted at annealing temperatures (68-70jC) that exceed the melting temperature of the primers to ensure the highest specificity for amplification of only methylated alleles present in the DNA sample. Cell lines positive and negative for methylation of these 14 genes and water blanks (bisulfite-modified and unmodified water) were used as controls for the MSP assays.
Because inflammatory, epithelial, and oral cells from the entire aerodigestive tract comprise the sputum sample, DNA from epithelial cells from the lower respiratory tract can be only a very small proportion of the total DNA in the sample. This scarcity of epithelial cell-based DNA can effect sampling to detect a rare methylation event because of the exfoliation of a minimal number of epithelial cells harboring a methylation change or the presence of a much higher number of inflammatory cells. To address the issue of stochastic sampling for this study and its effects on the sensitivity of the MSP assay, mixing experiments were conducted between cell lines positive and negative for methylation of the p16 gene. DNA isolated from Calu6 cells (p16 methylated) was added to DNA isolated from H2009 (p16 unmethylated) at dilutions ranging from 1:10 to 1:50,000. Bisulfite modification (1 Ag) was done on each sample and stage 1 MSP was conducted in triplicate, thereby sampling the modified DNA thrice. Stage 2 MSP for p16 was conducted on each sample. Methylation of the p16 gene was always detected in samples containing 1:10 to 1:10,000 methylated alleles. In contrast, methylation was detected in two of three samples containing 1:20,000 and one of three samples containing 1:50,000 methylated alleles (data not shown). Based on these results, we evaluated each sputum sample in duplicate beginning with the bisulfite modification step.
Two separate aliquots (1 Ag each) of DNA from each sputum sample were modified by bisulfite and subjected to MSP analysis for the 14 genes. A sample was called positive for methylation of a specific gene if either of the MSP assays were positive. The concordance between duplicate assays ranged between 65% and 95% for the 14 genes evaluated. As expected, the concordance between duplicate assays was inversely related to the prevalence for gene methylation in the sputum samples. A subset of samples (20%) that gave positive methylation products also was analyzed by methylation-sensitive restriction enzyme digestion of the resulting PCR product. The restriction digestion allows one to examine the methylationstate of CpGs within the amplified PCR product and serves as a control for false priming (17) . Digestion within at least one of the restriction sites was seen for all samples positively confirming methylation.
Data analysis. The data were summarized using frequencies and percents for categorical variables. Differences in distribution between cases and controls were first examined with v 2 . Logistic regression models were then examined to assess the association between moderate or more severe atypia and other risk factors. First, univariate models were examined, then multivariate models were developed that adjusted for the most important covariates. Because the matching broke down with the exclusion of some of the cases and controls, unconditional methods for multivariate analysis were used whereas retaining all matching variables in the models as covariates. Age was considered as a continuous variable in the analyses. Former smokers were defined as those individuals who had quit smoking 1 year or more at the time of questionnaire completion. Pack years of cigarette smoking at enrollment was defined as the average number of packs smoked per day multiplied by the number of years of smoking. FEV-1 was the value assessed at the time of cohort enrollment.
Associations were expressed as odds ratios and their corresponding 95% confidence intervals (CI). Analyses were conducted to assess the association with lung cancer for each gene separately, then for different combinations of genes together. Multiplicity of methylated genes was determined as the number of genes methylated in the sample collected closest to lung cancer diagnosis among a panel of six genes with the highest individual odds ratio (p16, PAX5-b, MGMT, DAPK, GATA5, and RASSF1A). Those analyses were also stratified by the length of time between the sputum collection and lung cancer diagnosis (>18 months versus within 18 months of diagnosis). The relationship between cytologic atypia and methylation was assessed, as was the relationship between methylation and the histologic type of lung cancer. Statistical significance was expressed by P values and 95% CI. However, because these were exploratory analyses, the type 1 error rate for some of the associations may be underestimated by the P values and 95% CI expressed in the tables, especially in the analysis of multiplicity among the genes in panels constructed based on the strength of association with lung cancer. All analyses were carried out using Statistical Analysis Software (version 8.1, SAS Institute, Inc., Cary, NC).
Results
Exposure history, sputum cytology, and pathology. Key demographic variables for cases and controls are summarized in Table 1 . The only significant difference seen was a greater proportion of former smokers among controls than cases. With respect to longitudinal follow-up, less than two sputum samples were available for evaluation from each case and control (Table 1) . Therefore, sputum samples collected proximal to lung cancer diagnosis for the incident cases and controls were examined for gene promoter methylation. Sputum adequacy defined as the presence of deep lung macrophages or Curschmann's spiral (23) was observed for 93% of the proximal sputum collected from cases and controls. Moderate atypia was present in sputum from 35 subjects and severe atypia from 10 subjects. The distribution of tumor histology among the 98 cases was 20% squamous cell carcinoma, 28% adenocarcinoma, 7% large cell, 8% small cell, and 37% carcinoma (subtype not specified).
Gene promoter methylation in sputum. Examples of the first and second stages of the nested PCR assay used to evaluate promoter methylation status for the p16, MGMT, DAPK, and RASSF1A genes and results for a stage 2 PCR for detection of a methylated p16 gene are shown in Fig. 1 . The individual odds ratio in the proximal sputum sample ranged from 0.7 to 1.9 for detecting methylation of a specific gene in cases versus controls after adjustment for age, sex, FEV1, pack years, and current smoking status ( Table 2 ). The strongest association was the f2-fold increased risk seen for the p16 gene. In addition, the detection of cytologic atypia (moderate or severe) was associated with a 1.7-fold increased risk for lung cancer. Because the proximal sputum was collected from 15% and 25% of cases >2 and 4 years (up to 72 months), respectively, prior to cancer diagnosis, we evaluated whether the prevalence for methylation of these biomarkers increased in the months leading up to lung cancer diagnosis. An increase in odds for methylation ranging from 1.5-to 2.2-fold was seen for each of the p16, PAX5 b, MGMT, DAPK, RASSF1A, GATA4, and GATA5 genes in cases compared with controls when comparing methylation in sputum samples collected within 18 months of diagnosis (Table 3 ). The odds ratio for cytologic atypia also increased to 2.0. In contrast, only the p16 gene was associated with an adjusted odds ratio that exceeded 1.5 in cases compared with controls when comparing methylation in sputum samples collected >18 months from cancer diagnosis ( Table 3) .
The relationships between gene-specific promoter methylation in sputum and tumor histology and cytology were examined for the p16, MGMT, PAX5 a, PAX5 b, DAPK, GATA4, GATA5, and RASSF1A genes. These genes were selected because they exhibit the largest increase in odds ratio when examining all proximal sputum or specimens collected within 18 months (Tables 2 and 3 ). Patterns of gene methylation were not different between specific histologic types of lung cancer (data not shown). Only the prevalence for methylation of the MGMT gene was positively associated with increasing cytologic changes (moderate atypia, severe dysplasia; P value for trend <0.04). The presence of cytologic atypia in sputum samples did not predict for specific tumor histology (data not shown). Field cancerization effects in high-risk smokers will likely dictate the development of a gene panel for early detection of lung cancer that focuses on assessing the prevalence for promoter hypermethylation of multiple genes in individual sputum specimens. This was evaluated by using a panel of genes that included p16, MGMT, DAPK, RASSF1A, PAX5 b, and GATA5. These genes were selected because their individual odds ratios were >1.5 in proximal sputum samples collected within 18 months of lung cancer diagnosis (Table 3 ). This approach yielded the most important finding of our study: cases with methylation of three or more genes in their sputum that was collected within 18 months of diagnosis had a 6.5-fold increased risk for lung cancer (95% CI, 1.2-35.5; Table 4 ). This represents a sensitivity and specificity for predicting lung cancer of 64%. Additional analyses (data not shown) of four or five positive markers in this panel did not show any greater discrimination for case status than the three or more markers described above. The addition of cytology as a biomarker to the multivariate models containing the methylation markers did not substantially alter either the methylation odds ratios or the cytologic atypia odds ratio, as methylation and cytologic atypia were not associated in these samples. For sputum samples collected >18 months before cancer diagnosis, a 1.5-fold greater odds for methylation of three or more genes was seen in cases compared with controls (Table 4) .
Discussion
This is the first study to prospectively examine a large panel of genes for their sensitivity and specificity for predicting lung cancer development in a cohort of very high-risk subjects. A key finding was the increase in detection of some genes in sputum samples collected within 18 months versus >18 months prior to cancer diagnosis. Furthermore, methylation of three or more genes in sputum collected within 18 months of diagnosis was associated with a 6.5-fold increase in the risk for lung cancer. This significant finding supports our hypothesis of an expanding field of precancerous changes throughout the aerodigestive tract that exfoliates cells with increasing frequencies of genetic and epigenetic changes as cancer develops. The fact that gene promoter methylation in sputum was not associated with a particular histologic diagnosis of lung cancer also substantiates the utility of gene promoter methylation as a biomarker for predicting lung Table 2 . Prevalence and odds for gene promoter methylation and cytologic atypia in proximal sputum samples cancer. It is highly unlikely that asymptomatic subjects with early stage lung cancer will exfoliate only cells specific to a small (<1 cm) lesion. Rather, as the field cancerization process grows in the lungs, more cells are exfoliated containing methylated genes, and the probability for an early lung tumor is increased (20) . As expected, the proportion of controls with three or more methylated genes was similar in sputum collected within or >18 months before diagnosis of cancer in the matched case. Furthermore, multiplicity for methylation in sputum collected from cases >18 months from cancer diagnosis was also quite similar to both groups of controls. Additional longitudinal studies of this type would be required to continue evaluating how the prevalence for gene methylation in sputum changes closer to cancer diagnosis. Detecting lung cancer 12 to 18 months prior to clinical symptoms will likely affect the *The genes examined included p16, MGMT, PAX5 b, DAPK, GATA5, and RASSF1A. cCases (n = 52) and controls (n = 47) comprised the study group for sputum samples collected within 18 months of cancer diagnosis. Cases (n = 46) and controls (n = 45) comprised the study group for sputum samples collected >18 months prior to cancer diagnosis. bAdjusted for age, sex, FEV1, pack years, and current smoking status. *Cases (n = 52) and controls (n = 47) comprised the study group for sputum samples collected within 18 months of cancer diagnosis. Cases (n = 46) and controls (n = 45) comprised the study group for sputum samples collected >18 months prior to cancer diagnosis. cAdjusted for age, sex, FEV1, pack years, and current smoking status. bModerate atypia or worse. management of this disease through ''stage reduction'' that will allow for an increase in the number of cases for which surgical resection can be done. The six genes that showed the highest individual odds ratios for distinguishing incident cases from controls are inactivated at different stages of lung cancer development. Methylation of p16 is one of the earliest epigenetic changes seen in the lungs of smokers. P16 is detected in histologically normal bronchial epithelium from some smokers, in alveolar hyperplasia, and in lesions that are precursors to squamous cell carcinoma (17, 20, 36) . In contrast, inactivation of MGMT is rare (8%) in hyperplasia, metaplasia, and dysplasia within the central airways (26) . Methylation of DAPK is seen in alveolar hyperplasia in a murine model of lung cancer (37) . The lack of methylation of RASSF1A in bronchial epithelium from smokers and the low prevalence of methylation seen in sputum from this and other studies support the inactivation of this gene as a later event in the development of preinvasive cancer (17, 38) . The timing for methylation of the PAX5 b and GATA5 genes in lung cancer development has not been characterized. The genes examined also have diverse cellular functions that include cell cycle regulation (p16 and PAX5 b), apoptosis (DAPK and RASSF1A), signal transduction (GATA5), and DNA repair (MGMT; refs. [39] [40] [41] [42] [43] [44] [45] . These functions may provide a biological explanation for their combined ability in predicting lung cancer.
The panel of six genes most associated with lung cancer risk has both sensitivity and specificity of 65%. This level of specificity is not high enough for prospective screening studies of the general population at risk for lung cancer development. However, considering the very high-risk status of the cohort studied, our results are encouraging and may be somewhat understated. In the present nested case-control study, all patients have chronic obstructive pulmonary disease (COPD) that increases risk for lung cancer by f2.5-fold, and 65% of subjects have a smoking history of z50 pack years. This has resulted in a 1% to 2% incidence of new lung cancer cases each year in the cohort, and in fact, two of the controls selected became cases during the course of this study. This is in contrast to a yearly overall risk of 0.3% for all current and former smokers. The high rate of comorbidity (60% of selected controls are now deceased) makes it impossible to determine through follow-up how many of the selected controls may become a case. The controls from this study had exposures (smoking history, COPD) that were greater than the cancer-free smokers examined for methylation of the p16 and MGMT genes in our original study of squamous cell carcinoma (12) . This likely accounts for the higher prevalence of gene methylation in sputum from controls in the current study. We also recently conducted a study examining methylation of the p16, MGMT, DAPK, RASSF1A, H-cadherin, PAX5 a, and PAX5 b genes in sputum from 121 cancer-free women with an average smoking history of 40 pack years and a 25% incidence of COPD. Compared with cancer-free controls in the current study, a similar prevalence for methylation was seen for methylation of the p16, RASSF1A, and H-cadherin genes in sputum collected from these women, whereas the prevalence for methylation of the other four genes was 2-to 5-fold lower (38) . Thus, the controls from the Colorado cohort may not reflect the average smoker's risk for lung cancer. In this regard, the present study sets the stage for large studies of smokers with more typical risk for lung cancer.
Our work also emphasizes a clear need to evaluate other promising genes in sputum from this ongoing prospective study for their potential to improve the sensitivity and specificity of this current gene panel (45) (46) (47) . The optimized gene panel will ultimately be assessed for performance in prospective trials to characterize it's clinical utility. Validation will likely entail screening a high-risk population followed by clinical evaluation using spiral computed tomography and/or bronchoscopy for individuals whose methylation profile conveys the highest risk for early lung cancer. Future assessments will also include the application of machine learning approaches to the identification of combinations of biomarkers that optimize the screening variables of sensitivity and specificity. Our current findings highlight the promise that developing a panel of genes whose inactivation by promoter hypermethylation in sputum can be used to sensitively and specifically identify people at high risk for lung cancer incidence, allowing careful monitoring to achieve the earliest possible diagnosis and intervention for this deadly malignancy.
